Until Archipelago Holdings
Thankfully, that didn't get in the way of subscribers to our Motley Fool Rule Breakers newsletter service. David Gardner recommended the stock in the February issue when it was trading at just $20.42 a share. The discovery process was catapulted into motion after the NYSE Group deal was announced. The stock has gone on to more than double, closing yesterday at a healthy perch of $44.50.
Archipelago provided another glimpse as to why NYSE Group wanted its hands on it when it released its June trading numbers yesterday. ArcaEx was responsible for 3.3% of all of the NYSE-listed stock trading that took place last month. That was more than double its 1.5% market share a year earlier.
Archipelago's presence was even greater on rival exchanges. ArcaEx accounted for 29.1% and 22.7% of the market trading volume on the American Stock Exchange and Nasdaq, respectively. More than a fifth of all trades for Intel
It's not necessarily ironic that an exchange should be coveted by market traders. Archipelago isn't even alone; The Chicago Mercantile Exchange
Ahhh, the sweet smell of consolidation.
Some other places to go from here:
- This is how it all went down between the two companies back in April.
- Check out our Broker Center to learn more about the trade trade.
Which Rule Breakers stock pick do you think will double next? There are two other recent selections that are up by more than 60%. Curious to learn more about this ultimate growth stock investing strategy? Take us up on a free 30-day trial subscription.
Longtime Fool contributor Rick Munarriz thinks that bids and asks are romantic in the appropriate context. He does not own shares in any of the companies in this story. The Fool has a disclosure policy. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
More from The Motley Fool
Why Netflix, Inc. Stock Jumped 13% This Morning
The streaming video pioneer added 8.3 million new subscribers in the fourth quarter -- more than 30% better than expected.
Better Buy: Micron vs. NVIDIA
You might be surprised by the winner.
Why Amarin Corporation Stock Is Surging Today
Vascepa's long-awaited cardiovascular outcomes data are close at hand.